Navigation thread
Navigation thread
Unit of Cancer immunotherapy
Cancer immunotherapy involves passive and active forms: (1) passive (monoclonal antibodies); and (2) active (adoptive cellular immunotherapy), using lymphocytes taken directly from the tumour or blood, which may or may not be genetically modified.
The fundamental mission of this Functional Unit is the clinical coordination of Hospital Clínic Barcelona's adoptive cell immunotherapy, as well as collaborative projects with other public or private institutions, in coordination with the Immunotherapy Section of the Immunology Department.
Therefore, the general objectives are as follows:
- Consolidate and strengthen the academic and commercial therapy with modified T lymphocytes (CAR T-cell therapy) already available.
- Collaborate in the development of new CAR T-cell products, other cell immunotherapy options (e.g. TILs and TCRs) and bispecific antibodies.
- Promote the state network of cell immunotherapy.
- To promote combination studies with other more conventional strategies (e.g. immune checkpoint inhibitors, radiotherapy, etc.).
